Joana Nicolau

Glucagon-like peptide-1 (GLP-1) receptor agonist drugs, used to control obesity and type 2 diabetes, are associated with changes in food purchasing in favour of healthier options. This result, published in the journal JAMA Network Open, was obtained by analysing nearly two million shopping receipts from more than 1,100 participants in Denmark. Those who started treatment with GLP-1 drugs began to make purchases with fewer calories, sugars, saturated fats and carbohydrates, along with a modest increase in protein content. A decrease in the purchase of ultra-processed foods was also observed.

In mice, administering semaglutide - the molecule marketed under the name Ozempic or Wegovy - does not reduce muscle mass as much as expected, but it does affect muscle function, according to a study published in Cell Metabolism. In some types of muscle, the experiment measured a decrease in force-generating capacity of about 20%, disproportionately greater than the loss of muscle mass.